MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice
Standard
MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice. / Göbel, Carolin; Godbole, Shweta; Schoof, Melanie; Holdhof, Dörthe; Kresbach, Catena; Loose, Carolin; Neumann, Julia; Schüller, Ulrich.
In: ACTA NEUROPATHOL COM, Vol. 11, No. 1, 02.11.2023, p. 174.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice
AU - Göbel, Carolin
AU - Godbole, Shweta
AU - Schoof, Melanie
AU - Holdhof, Dörthe
AU - Kresbach, Catena
AU - Loose, Carolin
AU - Neumann, Julia
AU - Schüller, Ulrich
N1 - © 2023. The Author(s).
PY - 2023/11/2
Y1 - 2023/11/2
N2 - Group 3 medulloblastoma is one of the most aggressive types of childhood brain tumors. Roughly 30% of cases carry genetic alterations in MYC, SMARCA4, or both genes combined. While overexpression of MYC has previously been shown to drive medulloblastoma formation in mice, the functional significance of SMARCA4 mutations and their suitability as a therapeutic target remain largely unclear. To address this issue, we combined overexpression of MYC with a loss of SMARCA4 in granule cell precursors. Both alterations did not increase proliferation of granule cell precursors in vitro. However, combined MYC overexpression and SMARCA4 loss successfully induced tumor formation in vivo after orthotopic transplantation in recipient mice. Resulting tumors displayed anaplastic histology and exclusively consisted of SMARCA4-negative cells although a mixture of recombined and non-recombined cells was injected. These observations provide first evidence for a tumor-promoting role of a SMARCA4 deficiency in the development of medulloblastoma. In comparing the transcriptome of tumors to the cells of origin and an established Sonic Hedgehog medulloblastoma model, we gathered first hints on deregulated gene expression that could be specifically involved in SMARCA4/MYC driven tumorigenesis. Finally, an integration of RNA sequencing and DNA methylation data of murine tumors with human samples revealed a high resemblance to human Group 3 medulloblastoma on the molecular level. Altogether, the development of SMARCA4-deficient medulloblastomas in mice paves the way to deciphering the role of frequently occurring SMARCA4 alterations in Group 3 medulloblastoma with the perspective to explore targeted therapeutic options.
AB - Group 3 medulloblastoma is one of the most aggressive types of childhood brain tumors. Roughly 30% of cases carry genetic alterations in MYC, SMARCA4, or both genes combined. While overexpression of MYC has previously been shown to drive medulloblastoma formation in mice, the functional significance of SMARCA4 mutations and their suitability as a therapeutic target remain largely unclear. To address this issue, we combined overexpression of MYC with a loss of SMARCA4 in granule cell precursors. Both alterations did not increase proliferation of granule cell precursors in vitro. However, combined MYC overexpression and SMARCA4 loss successfully induced tumor formation in vivo after orthotopic transplantation in recipient mice. Resulting tumors displayed anaplastic histology and exclusively consisted of SMARCA4-negative cells although a mixture of recombined and non-recombined cells was injected. These observations provide first evidence for a tumor-promoting role of a SMARCA4 deficiency in the development of medulloblastoma. In comparing the transcriptome of tumors to the cells of origin and an established Sonic Hedgehog medulloblastoma model, we gathered first hints on deregulated gene expression that could be specifically involved in SMARCA4/MYC driven tumorigenesis. Finally, an integration of RNA sequencing and DNA methylation data of murine tumors with human samples revealed a high resemblance to human Group 3 medulloblastoma on the molecular level. Altogether, the development of SMARCA4-deficient medulloblastomas in mice paves the way to deciphering the role of frequently occurring SMARCA4 alterations in Group 3 medulloblastoma with the perspective to explore targeted therapeutic options.
KW - Animals
KW - Humans
KW - Mice
KW - Brain Neoplasms/genetics
KW - Cerebellar Neoplasms/metabolism
KW - DNA Helicases/genetics
KW - Hedgehog Proteins/metabolism
KW - Medulloblastoma/metabolism
KW - Nuclear Proteins/genetics
KW - Transcription Factors/genetics
KW - Transcriptome
U2 - 10.1186/s40478-023-01654-2
DO - 10.1186/s40478-023-01654-2
M3 - SCORING: Journal article
C2 - 37919824
VL - 11
SP - 174
JO - ACTA NEUROPATHOL COM
JF - ACTA NEUROPATHOL COM
SN - 2051-5960
IS - 1
ER -